Abstract 1710: Pharmacologic Profile of SCH 530348, a Novel Oral Antiplatelet Agent Selective for the Protease-Activated Receptor-1 (PAR-1)

Antiplatelet agents are a cornerstone of therapy for atherothrombotic disease. However, despite the proven efficacy of agents targeting the thromboxane A2 (aspirin) and P2Y12 ADP (clopidogrel, prasugrel) platelet activation pathways, the residual risk for ischemic events remains considerable. Binding of thrombin to the platelet PAR-1 is an important platelet activation pathway not targeted by existing agents. Inhibition of PAR-1 may thus provide incremental clinical benefits over aspirin and ADP receptor antagonists. PAR-1 receptors expressed on endothelial cells, smooth muscle cells, monocytes and neutrophils have been reported to mediate the pro-inflammatory and chemotactic responses to thrombin. In the present study, we report pharmacologic characterization of SCH 530348, a novel thrombin receptor antagonist (TRA) selective for PAR-1, using in vitro assays with human platelet membranes and cultured human coronary artery smooth muscle cells (HCASMC), and ex vivo platelet aggregation assays in cynomolgus monkeys. The affinity of SCH 530348 for the PAR-1 receptor was determined in human platelet membranes. Functional studies involving calcium transients, thymidine incorporation, and receptor kinetics were performed in HCASMC. The oral antiplatelet effects of SCH 530348 in cynomolgus monkeys were evaluated in ex vivo platelet aggregation assays. SCH 530348 exhibited high affinity for PAR-1 receptor. SCH 530348 potently inhibited thrombin-stimulated calcium transients and thymidine incorporation in HCASMC, and displayed slow dissociation from PAR-1 receptor. In cynomolgus monkeys, SCH 530348 administered orally at doses ranging from 0.1 mg/kg to 3 mg/kg, provided rapid, complete, and sustained inhibition of thrombin receptor agonist peptide (TRAP)-induced ex vivo platelet aggregation for 24 hours. Significant inhibition of TRAP-induced platelet aggregation was maintained at 48 hours after dosing of SCH 530348. SCH 530348 is a highly selective, potent, and orally active PAR-1 antagonist. Inhibition of PAR-1 by SCH 530348 may translate into beneficial clinical effects in patients with atherothrombotic disease, and this hypothesis is currently being evaluated in 2 large trials.

Download Full-text

Phospholipase C from Clostridium Perfringens Induces Human Platelet Aggregation in Plasma

Thrombosis and Haemostasis ◽

10.1055/s-0038-1642761 ◽

1988 ◽

Vol 59 (02) ◽

pp. 236-239 ◽

Cited By ~ 2

Author(s):

Giovanna Barzaghi ◽

Chiara Cerletti ◽

Giovanni de Gaetano

Keyword(s):

Platelet Aggregation ◽

Receptor Antagonist ◽

Phospholipase C ◽

Clostridium Perfringens ◽

Human Platelet ◽

Ex Vivo ◽

Platelet Rich Plasma ◽

Platelet Activating Factor ◽

Inhibitory Effect ◽

Thromboxane Receptor Antagonist

SummaryWe studied the aggregating effect of different concentrations of phospholipase C (PLC) (extracted from Clostridium perfringens) on human platelet-rich plasma (PRP). PRP was preincubated with PLC for 3 min at 37° C and the platelet aggregation was followed for 10 min. The threshold aggregating concentration (TAG) of PLC was 3-4 U/ml.We also studied the potentiation of PLC with other stimuli on platelet aggregation. Potentiating stimuli, such as arachidonic acid (AA), ADP. Platelet Activating Factor (PAF) and U-46619 (a stable analogue of cyclic endoperoxides) were all used at subthreshold concentrations. We also studied the possible inhibitory effect of aspirin, apyrase, TMQ, a prostaglandin endoper- oxide/thromboxane receptor antagonist and BN-52021, a PAF receptor antagonist. Only aspirin and apyrase were able to reduce aggregation induced by PLC alone and PLC + AA and PLC + ADP respectively. TMQ and BN-52021 were inactive. In ex vivo experiments oral aspirin (500 mg) partially inhibited platelet aggregation induced by PLC alone, PLC + AA and PLC + ADP 2 and 24 h after administration. Aspirin 20 mg for 7 days also reduced aggregation induced by PLC + AA.

Download Full-text

Ex vivo evaluation of anti-GPVI antibody in Cynomolgus monkeys: Dissociation between anti-platelet aggregatory effect and bleeding time

Thrombosis and Haemostasis ◽

10.1160/th06-05-0266 ◽

2006 ◽

Vol 96 (08) ◽

pp. 167-175 ◽

Cited By ~ 27

Author(s):

Yutaka Matsumoto ◽

Hisao Takizawa ◽

Kazuhiro Nakama ◽

Xiaoqi Gong ◽

Yoshihisa Yamada ◽

...

Keyword(s):

Platelet Aggregation ◽

Bleeding Time ◽

Ex Vivo ◽

Thrombus Formation ◽

Inhibitory Effect ◽

Bleeding Tendency ◽

Fab Fragment ◽

Dose Escalation Study ◽

Cynomolgus Monkeys ◽

Induced Aggregation

SummaryRecent progress in the understanding of thrombus formation has suggested an important role of glycoprotein (GP)VI. In contrast to its pivotal role in collagen-induced platelet activation, it has been suggested that its blockade does not induce massive bleeding tendency. To demonstrate the dissociation between inhibitory effect on platelet aggregation and bleeding by GPVI blockade, we examined the effects of Fab fragment of OM2, an anti-human GPVI monoclonal antibody on ex vivo collagen-induced platelet aggregation and skin bleeding time after intravenous injection in cynomolgus monkeys. In a dose-escalation study, OM2 potently (>80%) inhibited collagen-induced platelet aggregation at the cumulative dose of 0. 2 mg/kg with a slight prolongation of bleeding time (1. 3 times baseline value). Furthermore, at 18. 8 mg/kg, the highest dose tested, prolongation of bleeding time was still mild (1. 9 times). In contrast, abciximab, Fab fragment of anti-GPIIb/IIIa antibody prolonged bleeding time by 5. 0 times at 0. 35 mg/kg, the lowest effective dose on platelet aggregation. Ina pharmacodynamic study,a bolus injection of OM2 at 0. 4 mg/kg produced potent inhibition of collagen-induced aggregation up to six hours after injection, showing longer half-life than that of abciximab. The injection of OM2 Fab did not induce thrombocytopenia and GPVI depletion in monkeys. These results suggest that blockade of GPVI by antibody can exerta potent inhibitory effect on collagen-induced platelet aggregation with a milder prolongation of bleeding time than blockade of GPIIb/IIIa. This study indicates that OM2 has the potential to be developed as a new class of therapeutic tool.

Download Full-text

In vitro and ex vivo effect of cimetidine on human platelet aggregation

Thrombosis Research ◽

10.1016/0049-3848(86)90204-5 ◽

1986 ◽

Vol 42 (1) ◽

pp. 113-114

Author(s):

B. Gachályi ◽

K. Tihanyi ◽

Á. Vas ◽

B. Nádas ◽

A. Káldor

Keyword(s):

Platelet Aggregation ◽

Human Platelet ◽

Ex Vivo ◽

Human Platelet Aggregation

Download Full-text

Inhibition of Human Platelet Function Induced by Sulphinpyrazone

10.1055/s-0038-1665778 ◽

1979 ◽

Author(s):

E Maguire ◽

G Pay ◽

J Turney ◽

R Wallis ◽

M Weston ◽

...

Keyword(s):

Arachidonic Acid ◽

Platelet Count ◽

Platelet Aggregation ◽

Bleeding Time ◽

Human Platelet ◽

Ex Vivo ◽

Term Treatment ◽

Second Phase ◽

Maximum Plasma ◽

At Iii

A single 400 mg dose of sulphinpyrazone (S) administered orally to 5 volunteers inhibited arachidonic acid (AA)-induced platelet aggregation and platelet MDA production ex vivo biphasically. The initial inhibitory phase coincided with the maximum plasma concentration of S but the second phase occurred 24 h after dosing when no plasma S was detectable. At 2 h the concentration of AA inducing half-maximal aggregation was increased 1.95 times and at 24 h by 1.61 times. Dosing 7 volunteers with 200 mg q.d.s. for 7 days and 5 volunteers with 400 mg b.d.s. for 5 days also led to inhibitory activity against AA-induced platelet aggregation and MDA production which declined to zero 48 h after the last dose. Platelet count, fibrinogen, F VIII, β-TG and AT III were not influenced by the longer term treatment but bleeding time was slightly extended in all but one subject.

Download Full-text

Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race

Blood ◽

10.1182/blood-2014-04-572479 ◽

2014 ◽

Vol 124 (23) ◽

pp. 3450-3458 ◽

Cited By ~ 71

Author(s):

Leonard C. Edelstein ◽

Lukas M. Simon ◽

Cory R. Lindsay ◽

Xianguo Kong ◽

Raúl Teruel-Montoya ◽

...

Keyword(s):

Platelet Aggregation ◽

Platelet Function ◽

High Frequency ◽

Human Platelet ◽

Thrombin Receptor ◽

Common Variants ◽

Key Points ◽

The Common

Key Points White individuals have a high frequency of the common PAR4 gene (F2RL3) variant Ala120; blacks have a high frequency of Thr120. PAR4 Thr120 induces greater signaling and is associated with greater platelet aggregation and reduced inhibition by a PAR4 antagonist.

Download Full-text

Amyloid β protein negatively regulates the human platelet activation induced by thrombin receptor-activating protein

10.21203/rs.3.rs-391777/v1 ◽

2021 ◽

Author(s):

Daisuke Mizutani ◽

Haruhiko Tokuda ◽

Takashi Onuma ◽

Kodai Uematsu ◽

Daiki Nakashima ◽

...

Keyword(s):

Platelet Aggregation ◽

Intracerebral Hemorrhage ◽

Platelet Activation ◽

Human Platelet ◽

Amyloid Β ◽

Human Platelets ◽

The Other ◽

Thrombin Receptor ◽

Amyloid Β Protein ◽

Β Protein

Abstract Background: Amyloid β protein (Aβ) is the main product derived from amyloid precursor protein (APP) by sequential enzymatic actions. Deposition of Aβ in the brain parenchyma or cerebral vessels is a primary morphological feature of Alzheimer’s disease (AD). In addition, abnormal accumulation of Aβ in the cerebral vessels is known as cerebral amyloid angiopathy (CAA), which is considered a risk factor for intracerebral hemorrhage, particularly in the elderly. CAA reportedly contributes to the development of vascular cognitive decline in addition to AD. On the other hand, human platelets are recognized as the principal components affecting the onset and progression of AD. Although there are several studies showing that Aβ directly modulates human platelet functions, the exact mechanism underlying the Aβ effects on human platelets remains to be elucidated.Methods: The present study investigated the effects of Aβ on human platelet activation using a platelet aggregometer with laser scattering, followed by western blot analysis and ELISA.Results: Aβ at doses up to 7 µM alone failed to affect platelet aggregation or platelet-derived growth factor (PDGF)-AB secretion. On the other hand, Aβ decreased the platelet aggregation induced by thrombin receptor-activating protein (TRAP), but not collagen or ADP. Aβ also suppressed platelet aggregation induced by SCP0237, a selective protease-activated receptor (PAR)-1 agonist, and A3227, a selective PAR-4 agonist. The PDGF-AB secretion and the phosphorylated-heat shock protein (HSP)27 release by TRAP were inhibited by Aβ. In addition, the TRAP-induced phosphorylation of JNK and the phosphorylation of p38 MAP kinase followed by phosphorylation of HSP27 were reduced by Aβ.Conclusion: The results of the present study strongly suggest that Aβ negatively regulates PAR-elicited human platelet activation. These findings may indicate one of the causes of intracerebral hemorrhage due to CAA.

Download Full-text

Effect of sulphinpyrazone on human platelet aggregation, 5- hydroxytryptamine release and adhesion ex vivo: comparison with naproxen.

British Journal of Clinical Pharmacology ◽

10.1111/j.1365-2125.1980.tb04833.x ◽

1980 ◽

Vol 9 (3) ◽

pp. 239-245 ◽

Cited By ~ 8

Author(s):

B Nunn ◽

FJ James

Keyword(s):

Platelet Aggregation ◽

Human Platelet ◽

Ex Vivo ◽

Human Platelet Aggregation

Download Full-text

THE DIHYDROPYRIDINE CALCIUM CHANNEL AGONIST, BAY K 8644, AND THE ANTAGONIST, NIFEDIPINE, INHIBIT U46619-INDUCED HUMAN PLATELET ACTIVATION BY COMPETITIVE BINDING TO THE THROMBOXANE A22/PGH2 RECEPTOR

10.1055/s-0038-1643756 ◽

1987 ◽

Author(s):

G J Johnson ◽

P C Dunlop ◽

M J Rabiet ◽

L A Leis ◽

AH L From

Keyword(s):

Platelet Aggregation ◽

Platelet Activation ◽

Competitive Inhibition ◽

Human Platelet ◽

Ex Vivo ◽

Competitive Binding ◽

Bay K 8644 ◽

Voltage Dependent ◽

Ca2 Channels

The dihydropyridine (DP) Ca2+ channel antagonist, nifedipine (NF), inhibits platelet aggregation .in vitro and ex vivo by an undefined mechanism. Inhibition of Ca2+ influx via Ca2+ channels is a postulated mechanism, but voltage-dependent Ca2+ channels have not been demonstrated in platelets. We previously observed that NF blocked thromboxane A2 (TXA2)-induced platelet aggregation and secretion. In order to further evaluate the mechanism of DP inhibition of platelet activation, we studied the effects of NF and BAY K 8644, (BAY), a DP with opposite (agonist) effects on muscle cells, on human platelet aggregation and secretion induced by the TXA2 mimic, U46619. We also observed the effects of DP on biochemical consequences of platelet activation: cytoplasmic ionized Ca2+ ([Ca2+]i) by fura-2 fluorescence; phosphorylation of 40,000 Dalton protein (40KP) substrate of protein kinase C by SDS-PAGE and [32p] counting; TXA2 formation by RIA of TXB2. 1μM BAY and 10μM NF inhibited the 2nd wave of platelet aggregation and secretion induced by ADP or epinephrine and blocked aggregation and secretion induced by U46619. A Schild plot gave a slope of -1 indicating competitive inhibition of U46619 by BAY (K1[=0.7μM).BAY and NF also blocked U46619-induced phosphorylation of 40KP, rise in [Ca2+]i and TXB2 formation. The (+)-(R) enantiomer of BAY (BAY+) was responsible for BAY inhibition. BAY, BAY(+), and the R enantiomer of another DP, 202-791, all functioned as competitive antagonists of [3H]-U4661 9 binding (K1[ for BAY=2.8 μM-comparable to known receptor antagonists, 13-azaprostanoic acid and BM 13.177; K1 for BAY(+)=0.69μM). Neither BAY nor NF inhibited[3H]-yohimbine binding to α adrenergic receptors.NF, BAY, BAY(+) and BAY(-) in nM concentrations slightly stimulated platelet aggregation,secretion and biochemical events induced by U46619 similar to their effects on muscle. Therefore, DP's do not inhibit platelet activation by blocking voltage-dependent Ca2+ channels. The mechanism of DP inhibition of TXA2-induced platelet activation is stereoselective, competitive binding to the TXA2/PGH2 receptor. DP's may exert similar effects on TXA2-induced vascular smooth muscle contraction.

Download Full-text

Favorable therapeutic index of an orally-active small-molecule antagonist of the platelet protease-activated receptor-4, BMS-986141, compared with the P2Y12 antagonist ticagrelor in cynomolgus monkeys

European Heart Journal ◽

10.1093/ehjci/ehaa946.3380 ◽

2020 ◽

Vol 41 (Supplement_2) ◽

Author(s):

P Wong ◽

J Banville ◽

R Wexler ◽

E Priestley ◽

A Marinier ◽

...

Keyword(s):

Platelet Aggregation ◽

Small Molecule ◽

Ex Vivo ◽

Antiplatelet Agent ◽

Thrombin Receptor ◽

Funding Source ◽

Private Company ◽

Post Dose ◽

Orally Active ◽

P2y12 Antagonist

Abstract Introduction BMS-986141 is an orally-active small-molecule platelet thrombin receptor antagonist selective for the protease-activated receptor-4 (PAR4), a human platelet thrombin receptor. Purpose This study assessed effects of BMS-986141 vs. the P2Y12 antagonist ticagrelor, a standard of care antiplatelet agent, on arterial thrombosis (AT), mesenteric bleeding time (MBT) and platelet aggregation in monkeys. Methods Studies were conducted in models of electrically-mediated carotid artery thrombosis and MBT in anesthetized monkeys. Monkeys were given a single oral dose of BMS-986141 (0.05, 0.1, 0.5 mg/kg) or vehicle (n=8/group). At 2 hr post-dose, in vivo AT, MBT as well as ex vivo platelet aggregation were monitored in the same animal. Ticagrelor was studied as a comparator and given as IV bolus plus infusion at 0.0023+0.017 to 0.075+0.6 (mg/kg+mg/kg/h) (n=5–6/group). Thrombus weight reduction, MBT increase over vehicle, and platelet aggregation inhibition were determined. Peak platelet aggregation responses to activation peptides selective for PAR4 (PAR4-AP, 12.5 μM) and PAR1 (PAR1-AP, 18 μM), to collagen (5 μg/ml) and to ADP (20 μM) were determined by whole blood aggregometry. Results BMS-986141 inhibited platelet aggregation induced by PAR4-AP in human and monkey blood in vitro with comparable IC50 of 1.8±0.3 and 1.2±0.3 nM, respectively. BMS-986141 at 0.5 mg/kg completely inhibited platelet aggregation induced by PAR4-AP but not PAR1-AP, ADP and collagen, suggesting PAR4 receptor selectivity. In the AT model, BMS-986141 at 0.05, 0.1 and 0.5 mg/kg reduced thrombus weight by 36±7*, 63±8*, and 88±3%*, respectively (*P<0.05 vs. vehicle). BMS-986141 increased MBT by up to 1.2-fold. In a separate study, ticagrelor at 0.0023+0.017, 0.0068+0.055, 0.0255+0.18 and 0.075+0.6 (mg/kg+mg/kg/h IV) reduced thrombus weight by 19±8, 36±5*, 76±6* and 89±1%*, and increased MBT by respectively by 1.7-, 6.4-*, >10-*, and >10-fold*, respectively (*P<0.05 vs. vehicle). Conclusion Comparable antithrombotic efficacy was observed between BMS-986141 and ticagrelor in monkeys. BMS-986141 exhibited lower MBT compared with ticagrelor at equivalent antithrombotic doses. This study suggests that PAR4 antagonism provides a potentially safer antiplatelet therapy. Funding Acknowledgement Type of funding source: Private company. Main funding source(s): Research was supported by Bristol-Myers Squibb

Download Full-text